[Alpha1-adrenoceptor subtypes and alpha1-adrenoceptor antagonists].
Alpha(1)-adrenoceptors are widely distributed in the human body and play important physiologic roles. Three alpha(1)-adrenoceptor subtypes (alpha(1A), alpha(1B) and alpha(1D)) have been cloned and show different pharmacologic profiles. In addition, a putative alpha(1)-adrenoceptor (alpha(1L) subtype) has also been proposed. Recently, three drugs (tamsulosin, naftopidil, and silodosin) have been developed in Japan for the treatment of urinary obstruction in patients with benign prostatic hyperplasia. In this review, we describe recent alpha(1)-adrenoceptor subclassifications and the pharmacologic characteristics (subtype selectivity and clinical relevance) of alpha(1)-adrenoceptor antagonists.
Muramatsu
Ikunobu
I
Division of Pharmacology, Department of Biochemistry and Bioinformative Sciences, University of Fukui School of Medicine, Japan. muramatsu@fmsrsa.fukui-med.ac.jp
Suzuki
Fumiko
F
Tanaka
Takashi
T
Yamamoto
Hatsumi
H
Morishima
Shigeru
S
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000595:Amino Acid Sequence; D000818:Animals; D003001:Cloning, Molecular; D015195:Drug Design; D004361:Drug Tolerance; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data; D009281:Naphthalenes; D010879:Piperazines; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy; D018340:Receptors, Adrenergic, alpha-1 / Q000737:chemistry / Q000145:classification* / Q000502:physiology; D013449:Sulfonamides; D000077409:Tamsulosin; D014524:Urethral Obstruction / Q000188:drug therapy / Q000209:etiology
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D009281:Naphthalenes; D010879:Piperazines; D018340:Receptors, Adrenergic, alpha-1; D013449:Sulfonamides; D000077409:Tamsulosin; C064357:naftopidil